| scholarly article | Q13442814 |
| P2093 | author name string | Jorgensen RA | |
| Angulo P | |||
| Lindor KD | |||
| Sylvestre PB | |||
| Abdelmalek MF | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | steatohepatitis | Q2335423 |
| P304 | page(s) | 2711-2717 | |
| P577 | publication date | 2001-09-01 | |
| P1433 | published in | The American Journal of Gastroenterology | Q7713501 |
| P1476 | title | Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study | |
| P478 | volume | 96 |
| Q57121856 | Q57121856 |
| Q26752487 | A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD |
| Q37401935 | AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives. |
| Q81221459 | Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells |
| Q35580451 | Advances in the Understanding and Treatment of Nonalcoholic Fatty Liver Disease |
| Q36329908 | Advances in the treatment of nonalcoholic fatty liver disease |
| Q79218992 | American Association of Clinical Endocrinologists Medical Guidelines for the Clinical Use of Dietary Supplements and Nutraceuticals |
| Q24243125 | Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis |
| Q36440119 | Antioxidant therapy in nonalcoholic steatohepatitis |
| Q35585469 | Antioxidants as therapeutic agents for liver disease |
| Q45077756 | Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis |
| Q55060254 | Betaine alleviates hepatic lipid accumulation via enhancing hepatic lipid export and fatty acid oxidation in rats fed with a high-fat diet. |
| Q93140451 | Betaine alleviates high glucose‑induced mesangial cell proliferation by inhibiting cell proliferation and extracellular matrix deposition via the AKT/ERK1/2/p38 MAPK pathway |
| Q44701004 | Betaine and nonalcoholic steatohepatitis |
| Q42923624 | Betaine and nonalcoholic steatohepatitis: back to the future? |
| Q50928336 | Betaine attenuates Alzheimer-like pathological changes and memory deficits induced by homocysteine. |
| Q58271879 | Betaine enhances the cellular survival via mitochondrial fusion and fission factors, MFN2 and DRP1 |
| Q35007696 | Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial |
| Q33840618 | Betaine improved adipose tissue function in mice fed a high-fat diet: a mechanism for hepatoprotective effect of betaine in nonalcoholic fatty liver disease |
| Q41463752 | Betaine improves nonalcoholic fatty liver and associated hepatic insulin resistance: a potential mechanism for hepatoprotection by betaine |
| Q42254829 | Betaine protects against high-fat-diet-induced liver injury by inhibition of high-mobility group box 1 and Toll-like receptor 4 expression in rats |
| Q48490461 | Betaine recovers hypothalamic neural injury by inhibiting astrogliosis and inflammation in fructose-fed rats |
| Q80194107 | Betaine resolves severe alcohol-induced hepatitis and steatosis following liver transplantation |
| Q36753502 | Betaine supplement alleviates hepatic triglyceride accumulation of apolipoprotein E deficient mice via reducing methylation of peroxisomal proliferator-activated receptor alpha promoter |
| Q46102690 | Betaine supplementation attenuates atherosclerotic lesion in apolipoprotein E-deficient mice |
| Q43746107 | Betaine: an old therapy for a new scourge |
| Q45983094 | Bile salt-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide as a hepatoprotective agent. |
| Q47831098 | Body heat responsive gelation of methylcellulose formulation containing betaine. |
| Q55234705 | Circulating Phospholipid Patterns in NAFLD Patients Associated with a Combination of Metabolic Risk Factors. |
| Q44700468 | Cognitive lifetime drinking history in nonalcoholic fatty liver disease: some cases may be alcohol related |
| Q34077617 | Constitutive induction of pro-inflammatory and chemotactic cytokines in cystathionine beta-synthase deficient homocystinuria |
| Q41832154 | Current and novel therapies for the treatment of nonalcoholic steatohepatitis |
| Q35124679 | Current best treatment for non-alcoholic fatty liver disease |
| Q34408961 | Current status of therapy in nonalcoholic Fatty liver disease |
| Q37859419 | Current therapeutic strategies in non-alcoholic fatty liver disease. |
| Q80552353 | Current treatments in nonalcoholic steatohepatitis |
| Q34195828 | Cystathionine beta-synthase null homocystinuric mice fail to exhibit altered hemostasis or lowering of plasma homocysteine in response to betaine treatment. |
| Q36726727 | Dietary choline and betaine assessed by food-frequency questionnaire in relation to plasma total homocysteine concentration in the Framingham Offspring Study |
| Q24197984 | Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis |
| Q24246447 | Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis |
| Q89464205 | Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH |
| Q46791373 | Effects of carnosine, taurine, and betaine pretreatments on diethylnitrosamine-induced oxidative stress and tissue injury in rat liver |
| Q42173119 | Effects of emodin on treating murine nonalcoholic fatty liver induced by high caloric laboratory chaw |
| Q99571242 | Fermented mulberry (Morus alba) leaves suppress high fat diet-induced hepatic steatosis through amelioration of the inflammatory response and autophagy pathway |
| Q53288154 | Folic acid supplementation during early hepatocarcinogenesis: cellular and molecular effects. |
| Q27333713 | Gallic acid ameliorated impaired glucose and lipid homeostasis in high fat diet-induced NAFLD mice |
| Q37629675 | Hepatic inflammation and progressive liver fibrosis in chronic liver disease |
| Q35669794 | Hepatic steatosis in obese patients: clinical aspects and prognostic significance. |
| Q42009283 | Hepatic very-low-density lipoprotein and apolipoprotein B production are increased following in vivo induction of betaine-homocysteine S-methyltransferase |
| Q54512059 | Hepatocyte growth factor overexpression ameliorates liver inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis. |
| Q36848280 | How should we manage patients with non-alcoholic fatty liver disease in 2007? |
| Q28281865 | Impaired de novo choline synthesis explains why phosphatidylethanolamine N-methyltransferase-deficient mice are protected from diet-induced obesity |
| Q36896377 | Increasing whole grain intake as part of prevention and treatment of nonalcoholic Fatty liver disease. |
| Q39638816 | Inhibition of interferon-α-induced signaling by hyperosmolarity and hydrophobic bile acids |
| Q42907435 | Inhibition of liver X receptor-α-dependent hepatic steatosis by isoliquiritigenin, a licorice antioxidant flavonoid, as mediated by JNK1 inhibition |
| Q34433803 | Involvement of AMP-activated protein kinase in beneficial effects of betaine on high-sucrose diet-induced hepatic steatosis |
| Q34076451 | Is there an effective therapy available for non-alcoholic fatty liver disease? |
| Q82069654 | Long-term effect of betaine on risk factors associated with the metabolic syndrome in healthy subjects |
| Q37613264 | Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis |
| Q30248650 | Mediterranean diet and nonalcoholic fatty liver disease: molecular mechanisms of protection. |
| Q56335024 | Metabolic Effects of Betaine: A Randomized Clinical Trial of Betaine Supplementation in Prediabetes |
| Q36572087 | Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases |
| Q42726470 | Multifocal nodular nonalcoholic steatohepatitis: resolution with rosiglitazone. |
| Q37935278 | NASH and atherosclerosis are two aspects of a shared disease: central role for macrophages |
| Q37437435 | New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). |
| Q36410552 | New treatments for nonalcoholic fatty liver disease |
| Q36475998 | Non alcoholic fatty liver disease: a clinical approach and review |
| Q35543956 | Non-alcoholic fatty liver disease: The diagnosis and management |
| Q35009628 | Non-alcoholic fatty liver disease: an overview |
| Q28248994 | Non-alcoholic fatty liver disease: need for a balanced nutritional source |
| Q26865113 | Non-alcoholic steatohepatitis: the role of oxidized low-density lipoproteins |
| Q34605022 | Nonalcoholic Fatty liver disease and obesity |
| Q36101753 | Nonalcoholic Fatty liver disease from the perspective of an internist |
| Q80966552 | Nonalcoholic Steatohepatitis |
| Q37699734 | Nonalcoholic Steatohepatitis: Clinical Presentation, Diagnosis, and Treatment |
| Q24555779 | Nonalcoholic fatty liver disease |
| Q37788538 | Nonalcoholic fatty liver disease: a challenge for pediatricians |
| Q36042906 | Nonalcoholic fatty liver disease: a clinical review |
| Q36219675 | Nonalcoholic fatty liver disease: a review |
| Q37681360 | Nonalcoholic fatty liver disease: a review and update |
| Q35996525 | Nonalcoholic fatty liver disease: a review of current understanding and future impact |
| Q37345907 | Nonalcoholic fatty liver disease: from clinical recognition to treatment |
| Q36382279 | Nonalcoholic fatty liver disease: from steatosis to cirrhosis |
| Q26992163 | Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine |
| Q35115696 | Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference |
| Q34993711 | Nonalcoholic steatohepatitis: what we know in the new millennium |
| Q43994762 | Noninvasive indices of fibrosis in NAFLD: starting to think about a three-hit (at least) phenomenon |
| Q37060098 | Obesity, inflammation, and the potential application of pharmaconutrition |
| Q50704509 | Open-label pilot study of folic acid in patients with nonalcoholic steatohepatitis. |
| Q47143693 | Opinion of the Scientific Panel on Dietetic products, nutrition and allergies [NDA] related to an application concerning the use of betaine as a novel food in the EU |
| Q33973031 | Organic solutes rescue the functional defect in delta F508 cystic fibrosis transmembrane conductance regulator. |
| Q80089315 | Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis (NASH) |
| Q38912628 | Oxidized LDL at the crossroads of immunity in non-alcoholic steatohepatitis |
| Q36179902 | Pathogenesis and management issues for non-alcoholic fatty liver disease |
| Q33606303 | Pathogenesis of non-alcoholic fatty liver disease. |
| Q36316956 | Pathophysiological basis for antioxidant therapy in chronic liver disease |
| Q37727707 | Personal model-assisted identification of NAD+ and glutathione metabolism as intervention target in NAFLD. |
| Q36747250 | Pharmacological treatment of non-alcoholic steatohepatitis: the current evidence. |
| Q37060124 | Phosphatidylcholine and choline homeostasis. |
| Q46689304 | Phosphatidylcholine homeostasis and liver failure |
| Q38102732 | Plant-based foods as a source of lipotropes for human nutrition: a survey of in vivo studies |
| Q36936358 | Present and future therapeutic strategies in non-alcoholic fatty liver disease |
| Q44381028 | Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study |
| Q34504586 | Quantitative analysis of hepatic fat fraction by single-breath-holding MR spectroscopy with T₂ correction: phantom and clinical study with histologic assessment |
| Q36360551 | Review article: Drug therapy for non-alcoholic fatty liver disease |
| Q35106643 | Review article: Non-alcoholic fatty liver disease |
| Q36433482 | Riboflavin-responsive trimethylaminuria in a patient with homocystinuria on betaine therapy |
| Q33607697 | Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver disease |
| Q36939985 | Role of transmethylation reactions in alcoholic liver disease |
| Q40300400 | S-Adenosylmethionine and betaine correct hepatitis C virus induced inhibition of interferon signaling in vitro |
| Q26829356 | S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility |
| Q27003912 | Strategies to rescue steatotic livers before transplantation in clinical and experimental studies |
| Q49232688 | Supplement of Betaine into Embryo Culture Medium Can Rescue Injury Effect of Ethanol on Mouse Embryo Development |
| Q47709635 | The Effects of Betaine on the Nuclear Fractal Dimension, Chromatin Texture, and Proliferative Activity in Hepatocytes in Mouse Model of Nonalcoholic Fatty Liver Disease. |
| Q37735049 | The betaine/GABA transporter and betaine: roles in brain, kidney, and liver |
| Q80101999 | The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study |
| Q35821156 | The ins and outs of mitochondrial dysfunction in NASH. |
| Q37235361 | The metabolic burden of methyl donor deficiency with focus on the betaine homocysteine methyltransferase pathway |
| Q34778237 | The metabolic syndrome and nonalcoholic fatty liver disease in children |
| Q34554574 | The use of selected nutrition supplements and complementary and alternative medicine in liver disease |
| Q30310183 | Therapeutic Options in Nonalcoholic Fatty Liver Disease |
| Q46772899 | Therapeutic options for nonalcoholic fatty liver disease and steatohepatitis |
| Q34273131 | Treatment of Nonalcoholic Fatty Liver Disease |
| Q36750279 | Treatment of fibrosis in nonalcoholic fatty liver disease |
| Q78631170 | Treatment of non-alcoholic fatty liver disease |
| Q24655572 | Treatment of non-alcoholic fatty liver disease |
| Q34592654 | Treatment of non-alcoholic fatty liver disease. |
| Q34156317 | Treatment options for nonalcoholic Fatty liver disease |
| Q55460608 | Treatment options for nonalcoholic fatty liver disease. |
| Q36304115 | Treatment strategies in nonalcoholic fatty liver disease |
| Q35681885 | Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial |
| Q37661014 | Vitamin E treatment in patients with nonalcoholic steatohepatitis: A six-month, open-label study of sixteen patients |
| Q80066082 | [Can metabolic steatohepatitis be treated?] |
| Q73650778 | [Current knowledge of nonalcoholic steatohepatitis] |
| Q73396434 | [Non-alcoholic steatohepatitis] |
Search more.